Sloan Kettering Institute Researchers retool CAR T cells to serve as 'micropharmacies' for cancer drugs

Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient’s own immune cells to fight cancer

Related Keywords

Davida Scheinberg ,Charles Nicolette ,National Institutes Of Health ,Molecular Pharmacology Program ,Chemical Biology Program ,Memorial Sloan Kettering Cancer Center ,Sloan Kettering Institute ,Synthetic Enzyme Armed ,Biology Program Chair Derek Tan ,Nature Chemical ,Experimental Therapeutics ,National Institutes ,